| This week's sponsor is Pfizer. | | | |
Top Stories Tuesday, November 29, 2016 AstraZeneca’s biologics arm MedImmune and synthetic biology co Abpro have joined forces on a new Ang2-VEGF research collab that will come together under a new spinout. Tuesday, November 29, 2016 Boehringer Ingelheim has teamed up with a Chinese research group to try to develop an effective drug treatment for the millions of people worldwide living with serious hearing loss. Tuesday, November 29, 2016 Amicus saw its shares down by 26% after news that its Fabry disease candidate migalastat did not meet the FDA’s requirements for a speedy review, and the biotech will also see any approval delayed until at least the end of the decade as it needs to create more data for the drug. Tuesday, November 29, 2016 Nivalis saw more than half its value wiped out after hours last night in reaction to the news that its cystic fibrosis candidate did not hit its targets, leaving its future hanging in the balance. Monday, November 28, 2016 The FDA is unlikely to review Advanced Accelerator Applications’ gastroenteropancreatic neuroendocrine tumor drug Lutathera in time for the Dec. 28 PDUFA date. The anticipated delay stems from faults with the format, traceability, uniformity and completeness of data sets submitted in the NDA. Monday, November 28, 2016 Researchers led by Yale University have singled out a protein that is responsible for transporting LDL cholesterol into cells. This target could lead to new treatments for LDL buildup, which can cause atherosclerosis and heart disease. Monday, November 28, 2016 Three major outside obstacles in the path of a clinical research? Bureaucracy, lack of funding and data. A joint working group formed by the Indian Council of Medical Research and Sun Pharma are outlining a plan to remove them in India. Monday, November 28, 2016 Sacramento’s Sutter Health is piloting Velano Vascular’s needle-free blood draw technology. It is among the first health systems in the country to offer the tech, which is based on the peripheral IV line that most in-patients already have. | | | British biotech Oxford BioMedica has penned a strategic alliance with Fierce 15 winner Orchard Therapeutics to help develop and supply lentiviral vectors for the manufacture of ex vivo gene therapy products. Release China-based Innovent Biologics has raised $260 million in a Series D round as it looks to build on its pipeline for cancer, CV and autoimmune diseases. Statement Blueprint Medicines says it has new proof-of-concept data from the early-stage test of its BLU-554 in patients with advanced hepatocellular carcinoma. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA DeviceTalks December 12, 2016 | Newport Beach, CA | 